Mercer Global Advisors Inc. ADV Grows Stake in Humana Inc. (NYSE:HUM)

Posted by on May 15th, 2023

Mercer Global Advisors Inc. ADV grew its holdings in Humana Inc. (NYSE:HUM – Get Rating) by 29.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 6,417 shares of the insurance provider’s stock after acquiring an additional 1,455 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Humana were worth $3,287,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in HUM. Cibc World Market Inc. increased its holdings in shares of Humana by 4.0% in the 1st quarter. Cibc World Market Inc. now owns 5,709 shares of the insurance provider’s stock valued at $2,484,000 after acquiring an additional 217 shares during the last quarter. Blair William & Co. IL increased its holdings in shares of Humana by 0.6% in the 1st quarter. Blair William & Co. IL now owns 5,660 shares of the insurance provider’s stock valued at $2,463,000 after acquiring an additional 32 shares during the last quarter. Cetera Investment Advisers grew its stake in Humana by 0.5% during the 1st quarter. Cetera Investment Advisers now owns 4,906 shares of the insurance provider’s stock worth $2,135,000 after buying an additional 26 shares during the last quarter. Sequoia Financial Advisors LLC grew its stake in Humana by 19.0% during the 1st quarter. Sequoia Financial Advisors LLC now owns 615 shares of the insurance provider’s stock worth $268,000 after buying an additional 98 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. grew its stake in Humana by 25.0% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 29,809 shares of the insurance provider’s stock worth $12,971,000 after buying an additional 5,964 shares during the last quarter. Hedge funds and other institutional investors own 93.38% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HUM. Cantor Fitzgerald began coverage on Humana in a research note on Thursday, April 20th. They set an “overweight” rating and a $597.00 price target on the stock. StockNews.com upgraded Humana from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, April 12th. Credit Suisse Group dropped their price target on Humana from $635.00 to $575.00 and set an “outperform” rating on the stock in a research note on Monday, February 6th. Morgan Stanley raised their price target on Humana from $620.00 to $637.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 11th. Finally, UBS Group dropped their price target on Humana from $645.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, February 2nd. Two equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Humana presently has an average rating of “Moderate Buy” and a consensus target price of $597.37.

Humana Stock Down 0.3 %

HUM opened at $527.35 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.39 and a quick ratio of 1.39. The business has a 50 day simple moving average of $508.59 and a 200-day simple moving average of $512.83. The stock has a market capitalization of $65.89 billion, a P/E ratio of 21.42, a P/E/G ratio of 1.40 and a beta of 0.72. Humana Inc. has a 12 month low of $410.87 and a 12 month high of $571.30.

Humana (NYSE:HUM – Get Rating) last posted its quarterly earnings results on Wednesday, April 26th. The insurance provider reported $9.38 EPS for the quarter, beating the consensus estimate of $9.25 by $0.13. The business had revenue of $26.74 billion during the quarter, compared to analysts’ expectations of $26.40 billion. Humana had a return on equity of 21.04% and a net margin of 3.26%. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period last year, the firm earned $8.04 EPS. On average, equities analysts anticipate that Humana Inc. will post 28.29 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 28th. Investors of record on Friday, June 30th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Thursday, June 29th. This represents a $3.54 annualized dividend and a yield of 0.67%. Humana’s dividend payout ratio is presently 14.38%.

Insider Buying and Selling

In related news, CEO Bruce D. Broussard sold 17,575 shares of Humana stock in a transaction on Monday, February 27th. The stock was sold at an average price of $505.85, for a total transaction of $8,890,313.75. Following the completion of the transaction, the chief executive officer now directly owns 70,040 shares of the company’s stock, valued at $35,429,734. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, insider Joseph C. Ventura sold 2,048 shares of the business’s stock in a transaction on Monday, February 27th. The stock was sold at an average price of $507.97, for a total value of $1,040,322.56. Following the completion of the transaction, the insider now directly owns 4,256 shares of the company’s stock, valued at $2,161,920.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Bruce D. Broussard sold 17,575 shares of the business’s stock in a transaction on Monday, February 27th. The stock was sold at an average price of $505.85, for a total value of $8,890,313.75. Following the completion of the transaction, the chief executive officer now directly owns 70,040 shares of the company’s stock, valued at $35,429,734. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,779 shares of company stock valued at $12,117,856. 0.32% of the stock is owned by insiders.

Humana Profile

(Get Rating)

Humana Inc engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts.

Featured Articles

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Get Rating).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.